STOCK TITAN

[Form 4] Relay Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Barclays Bank PLC is marketing an unsecured 14-month structured note – the Buffered Performance Leveraged Upside Securities (Buffered PLUS) – linked to the S&P 500 Index. The notes pay no coupons; investor return is delivered only at maturity on 16 Sep 2026.

Pay-out mechanics: (1) If the index closes above its initial level on the valuation date, holders receive the lesser of (a) $1,000 plus 150% of the index gain and (b) the maximum payment (at least $1,117.50, i.e. 111.75% of par). (2) If the index is flat or down by ≤5%, investors are repaid the $1,000 principal. (3) Losses begin beyond the 5% buffer; every additional 1% decline erodes 1% of principal down to the minimum payment of $50 (5% of par), exposing investors to up to a 95% loss.

Barclays estimates initial fair value at $924–$974, below the $1,000 offer price, reflecting selling commissions ($22.50 total per note) and hedging/structuring costs. The notes will not be listed; Barclays Capital Inc. may make a market but is not obliged to do so.

Key risks include: (i) credit risk of Barclays Bank PLC; (ii) U.K. Bail-in Power that could result in write-down or conversion of the securities; (iii) capped upside, high downside exposure and illiquidity; (iv) uncertain U.S. tax treatment. The product targets investors with a moderately bullish view on the S&P 500 who are comfortable foregoing dividends and accepting limited principal protection.

Barclays Bank PLC propone una nota strutturata non garantita della durata di 14 mesi – le Buffered Performance Leveraged Upside Securities (Buffered PLUS) – collegata all'indice S&P 500. Le note non pagano cedole; il rendimento per l'investitore viene corrisposto solo alla scadenza, il 16 settembre 2026.

Meccanismo di pagamento: (1) Se l'indice chiude sopra il livello iniziale alla data di valutazione, i detentori ricevono il minore tra (a) $1.000 più il 150% della crescita dell'indice e (b) il pagamento massimo (almeno $1.117,50, ossia il 111,75% del valore nominale). (2) Se l'indice è stabile o scende fino al 5%, gli investitori recuperano il capitale di $1.000. (3) Le perdite iniziano oltre la soglia del 5% di buffer; ogni ulteriore calo dell'1% riduce l'1% del capitale fino a un pagamento minimo di $50 (5% del valore nominale), esponendo gli investitori a una perdita massima del 95%.

Barclays stima un valore equo iniziale tra $924 e $974, inferiore al prezzo di offerta di $1.000, considerando commissioni di vendita (totale $22,50 per nota) e costi di copertura/strutturazione. Le note non saranno quotate; Barclays Capital Inc. potrà fare da market maker ma non è obbligata a farlo.

Rischi principali includono: (i) rischio di credito di Barclays Bank PLC; (ii) poteri di bail-in del Regno Unito che potrebbero comportare la svalutazione o conversione dei titoli; (iii) rendimento massimo limitato, elevata esposizione alle perdite e scarsa liquidità; (iv) trattamento fiscale USA incerto. Il prodotto si rivolge a investitori con una visione moderatamente positiva sull'S&P 500, disposti a rinunciare ai dividendi e ad accettare una protezione limitata del capitale.

Barclays Bank PLC está ofreciendo una nota estructurada no garantizada a 14 meses – las Buffered Performance Leveraged Upside Securities (Buffered PLUS) – vinculadas al índice S&P 500. Las notas no pagan cupones; el rendimiento para el inversor se entrega únicamente al vencimiento, el 16 de septiembre de 2026.

Mecánica de pago: (1) Si el índice cierra por encima de su nivel inicial en la fecha de valoración, los tenedores reciben el menor entre (a) $1,000 más el 150% de la ganancia del índice y (b) el pago máximo (al menos $1,117.50, es decir, 111.75% del valor nominal). (2) Si el índice se mantiene plano o baja hasta un 5%, los inversores recuperan el principal de $1,000. (3) Las pérdidas comienzan más allá del buffer del 5%; cada descenso adicional del 1% reduce el 1% del principal hasta el pago mínimo de $50 (5% del valor nominal), exponiendo a los inversores a una pérdida máxima del 95%.

Barclays estima un valor justo inicial entre $924 y $974, por debajo del precio de oferta de $1,000, reflejando comisiones de venta ($22.50 totales por nota) y costos de cobertura/estructuración. Las notas no estarán listadas; Barclays Capital Inc. puede hacer mercado pero no está obligado a hacerlo.

Riesgos clave incluyen: (i) riesgo crediticio de Barclays Bank PLC; (ii) poder de rescate (bail-in) del Reino Unido que podría resultar en la reducción o conversión de los valores; (iii) ganancia limitada, alta exposición a pérdidas y baja liquidez; (iv) tratamiento fiscal estadounidense incierto. El producto está dirigido a inversores con una visión moderadamente alcista del S&P 500 que están cómodos renunciando a dividendos y aceptando protección limitada del principal.

Barclays Bank PLC는 S&P 500 지수에 연동된 14개월 만기 무담보 구조화 상품인 Buffered Performance Leveraged Upside Securities (Buffered PLUS)를 마케팅하고 있습니다. 이 노트는 쿠폰이 지급되지 않으며, 투자 수익은 2026년 9월 16일 만기에만 지급됩니다.

지급 방식: (1) 평가일에 지수가 최초 수준을 초과 마감하면 보유자는 (a) $1,000에 지수 상승분의 150%를 더한 금액과 (b) 최대 지급액(최소 $1,117.50, 즉 액면가의 111.75%) 중 적은 금액을 받습니다. (2) 지수가 변동 없거나 5% 이하 하락 시, 투자자는 $1,000 원금을 돌려받습니다. (3) 5% 버퍼를 초과하는 손실부터 발생하며, 추가 1% 하락 시마다 원금의 1%가 감소하여 최소 지급액인 $50(액면가의 5%)까지 손실이 발생할 수 있어 최대 95% 손실에 노출됩니다.

Barclays는 초기 공정가치를 $924~$974로 추정하며, 이는 $1,000 제안가보다 낮으며 판매 수수료(노트당 총 $22.50) 및 헤지/구조화 비용을 반영한 것입니다. 이 노트는 상장되지 않으며, Barclays Capital Inc.가 시장 조성자가 될 수 있으나 의무는 아닙니다.

주요 위험으로는 (i) Barclays Bank PLC의 신용 위험, (ii) 영국의 베일인 권한으로 인해 증권의 감액 또는 전환 가능성, (iii) 상한이 있는 상승 잠재력, 높은 하락 위험 및 유동성 부족, (iv) 미국 세금 처리 불확실성이 있습니다. 이 상품은 S&P 500에 대해 다소 긍정적인 전망을 가진 투자자 중 배당금을 포기하고 제한된 원금 보호를 수용할 수 있는 투자자를 대상으로 합니다.

Barclays Bank PLC commercialise une note structurée non garantie de 14 mois – les Buffered Performance Leveraged Upside Securities (Buffered PLUS) – liées à l'indice S&P 500. Les notes ne versent aucun coupon ; le rendement est versé uniquement à l'échéance, le 16 septembre 2026.

Mécanisme de paiement : (1) Si l'indice clôture au-dessus de son niveau initial à la date d'évaluation, les détenteurs reçoivent le moindre entre (a) 1 000 $ plus 150 % de la hausse de l'indice et (b) le paiement maximum (au moins 1 117,50 $, soit 111,75 % du pair). (2) Si l'indice est stable ou en baisse jusqu'à 5 %, les investisseurs récupèrent le capital de 1 000 $. (3) Les pertes commencent au-delà de la marge tampon de 5 % ; chaque baisse supplémentaire de 1 % réduit 1 % du capital jusqu'au paiement minimum de 50 $ (5 % du pair), exposant les investisseurs à une perte maximale de 95 %.

Barclays estime la juste valeur initiale entre 924 $ et 974 $, inférieure au prix d'offre de 1 000 $, reflétant les commissions de vente (22,50 $ par note) et les coûts de couverture/structuration. Les notes ne seront pas cotées ; Barclays Capital Inc. peut assurer un marché mais n'y est pas obligé.

Risques clés : (i) risque de crédit de Barclays Bank PLC ; (ii) pouvoir de renflouement (bail-in) au Royaume-Uni pouvant entraîner une dépréciation ou une conversion des titres ; (iii) potentiel de gain plafonné, forte exposition à la baisse et illiquidité ; (iv) traitement fiscal américain incertain. Ce produit s'adresse aux investisseurs modérément optimistes sur le S&P 500, prêts à renoncer aux dividendes et à accepter une protection limitée du capital.

Barclays Bank PLC bietet eine unbesicherte strukturierte Note mit 14-monatiger Laufzeit an – die Buffered Performance Leveraged Upside Securities (Buffered PLUS) – die an den S&P 500 Index gekoppelt ist. Die Notes zahlen keine Kupons; die Rendite für den Anleger wird erst bei Fälligkeit am 16. September 2026 ausgezahlt.

Auszahlungsmechanismus: (1) Schließt der Index am Bewertungstag über seinem Anfangswert, erhalten die Inhaber den geringeren Betrag aus (a) $1.000 plus 150% des Indexzuwachses und (b) der maximalen Auszahlung (mindestens $1.117,50, also 111,75% des Nennwerts). (2) Liegt der Index unverändert oder bis zu 5% im Minus, erhalten die Anleger ihre $1.000 Kapital zurück. (3) Verluste beginnen über dem 5%igen Buffer; jeder weitere 1%-Rückgang mindert 1% des Kapitals bis zur Minimalzahlung von $50 (5% des Nennwerts), wodurch Anleger einem Verlust von bis zu 95% ausgesetzt sind.

Barclays schätzt den anfänglichen fairen Wert auf $924–$974, unter dem Angebotspreis von $1.000, was Verkaufsprovisionen (insgesamt $22,50 pro Note) sowie Absicherungs- und Strukturierungskosten widerspiegelt. Die Notes werden nicht börslich gehandelt; Barclays Capital Inc. kann als Market Maker auftreten, ist dazu aber nicht verpflichtet.

Hauptrisiken sind: (i) Kreditrisiko von Barclays Bank PLC; (ii) UK-Bail-in-Maßnahmen, die zu Abschreibungen oder Umwandlungen der Wertpapiere führen können; (iii) begrenztes Aufwärtspotenzial, hohes Abwärtsrisiko und Illiquidität; (iv) unsichere US-Steuerbehandlung. Das Produkt richtet sich an Anleger mit moderat bullischer Sicht auf den S&P 500, die auf Dividenden verzichten und eine begrenzte Kapitalsicherung akzeptieren können.

Positive
  • 150% leverage on upside performance up to the cap allows enhanced returns versus direct index exposure within the first ~7.8% gain.
  • 5% downside buffer absorbs modest index declines, returning full principal if losses stay within that band.
  • Minimum redemption value of $50 ensures some residual recovery even in severe market sell-offs.
  • Short 14-month maturity limits duration risk compared with longer-dated structured notes.
Negative
  • Investors can lose up to 95% of principal once the index falls more than 5%.
  • Upside is capped at roughly 11.75%, so gains beyond a ~7.8% index rise are forfeited.
  • Credit risk: repayment depends on Barclays Bank PLC; note is subject to U.K. Bail-in Power.
  • Illiquidity: no exchange listing; secondary market making is discretionary.
  • Estimated fair value ($924–$974) is below issue price, implying an immediate cost to investors.
  • Tax treatment uncertain; IRS could challenge prepaid-forward characterization.
  • No entitlement to S&P 500 dividends, reducing total return versus holding the index.

Insights

TL;DR Short-dated note offers 150% upside to a 7.8% index gain but risks up to 95% loss; credit and liquidity risks are material.

The Buffered PLUS is a typical yield-replacement instrument for retail clients seeking equity exposure with partial downside protection. The 150% leverage is attractive, but the low 7.833% breakpoint to hit the cap sharply truncates upside. The 5% buffer is thin relative to historical S&P 500 volatility and provides limited loss mitigation. Pricing is rich: the bank’s own model values the notes up to 7.6% below issue price, implying meaningful upfront cost to investors. Given the 14-month tenor, investors face significant event risk (earnings cycle, U.S. elections) while receiving no dividends. From Barclays’ perspective, the deal provides cheap funding and cross-sell for its structured-products desk. Overall impact: neutral for the issuer, but risk-heavy for buyers.

TL;DR Capped return, slim buffer and bail-in language create asymmetric downside; only suitable for niche risk profiles.

The security embeds multiple layers of risk: market (uncapped downside after 5%), credit (Barclays senior unsecured), regulatory (explicit consent to U.K. Bail-in Power), and liquidity (no listing, discretionary market-making). Investors effectively sell deep out-of-the-money put options for limited premium. Historical index drawdowns exceeding 5% in a 14-month window are common; stress testing shows a one-standard-deviation decline could cut principal by ~15%. Unless the investor is confident of a shallow, orderly rally, risk-adjusted return is inferior to a simple S&P ETF.

Barclays Bank PLC propone una nota strutturata non garantita della durata di 14 mesi – le Buffered Performance Leveraged Upside Securities (Buffered PLUS) – collegata all'indice S&P 500. Le note non pagano cedole; il rendimento per l'investitore viene corrisposto solo alla scadenza, il 16 settembre 2026.

Meccanismo di pagamento: (1) Se l'indice chiude sopra il livello iniziale alla data di valutazione, i detentori ricevono il minore tra (a) $1.000 più il 150% della crescita dell'indice e (b) il pagamento massimo (almeno $1.117,50, ossia il 111,75% del valore nominale). (2) Se l'indice è stabile o scende fino al 5%, gli investitori recuperano il capitale di $1.000. (3) Le perdite iniziano oltre la soglia del 5% di buffer; ogni ulteriore calo dell'1% riduce l'1% del capitale fino a un pagamento minimo di $50 (5% del valore nominale), esponendo gli investitori a una perdita massima del 95%.

Barclays stima un valore equo iniziale tra $924 e $974, inferiore al prezzo di offerta di $1.000, considerando commissioni di vendita (totale $22,50 per nota) e costi di copertura/strutturazione. Le note non saranno quotate; Barclays Capital Inc. potrà fare da market maker ma non è obbligata a farlo.

Rischi principali includono: (i) rischio di credito di Barclays Bank PLC; (ii) poteri di bail-in del Regno Unito che potrebbero comportare la svalutazione o conversione dei titoli; (iii) rendimento massimo limitato, elevata esposizione alle perdite e scarsa liquidità; (iv) trattamento fiscale USA incerto. Il prodotto si rivolge a investitori con una visione moderatamente positiva sull'S&P 500, disposti a rinunciare ai dividendi e ad accettare una protezione limitata del capitale.

Barclays Bank PLC está ofreciendo una nota estructurada no garantizada a 14 meses – las Buffered Performance Leveraged Upside Securities (Buffered PLUS) – vinculadas al índice S&P 500. Las notas no pagan cupones; el rendimiento para el inversor se entrega únicamente al vencimiento, el 16 de septiembre de 2026.

Mecánica de pago: (1) Si el índice cierra por encima de su nivel inicial en la fecha de valoración, los tenedores reciben el menor entre (a) $1,000 más el 150% de la ganancia del índice y (b) el pago máximo (al menos $1,117.50, es decir, 111.75% del valor nominal). (2) Si el índice se mantiene plano o baja hasta un 5%, los inversores recuperan el principal de $1,000. (3) Las pérdidas comienzan más allá del buffer del 5%; cada descenso adicional del 1% reduce el 1% del principal hasta el pago mínimo de $50 (5% del valor nominal), exponiendo a los inversores a una pérdida máxima del 95%.

Barclays estima un valor justo inicial entre $924 y $974, por debajo del precio de oferta de $1,000, reflejando comisiones de venta ($22.50 totales por nota) y costos de cobertura/estructuración. Las notas no estarán listadas; Barclays Capital Inc. puede hacer mercado pero no está obligado a hacerlo.

Riesgos clave incluyen: (i) riesgo crediticio de Barclays Bank PLC; (ii) poder de rescate (bail-in) del Reino Unido que podría resultar en la reducción o conversión de los valores; (iii) ganancia limitada, alta exposición a pérdidas y baja liquidez; (iv) tratamiento fiscal estadounidense incierto. El producto está dirigido a inversores con una visión moderadamente alcista del S&P 500 que están cómodos renunciando a dividendos y aceptando protección limitada del principal.

Barclays Bank PLC는 S&P 500 지수에 연동된 14개월 만기 무담보 구조화 상품인 Buffered Performance Leveraged Upside Securities (Buffered PLUS)를 마케팅하고 있습니다. 이 노트는 쿠폰이 지급되지 않으며, 투자 수익은 2026년 9월 16일 만기에만 지급됩니다.

지급 방식: (1) 평가일에 지수가 최초 수준을 초과 마감하면 보유자는 (a) $1,000에 지수 상승분의 150%를 더한 금액과 (b) 최대 지급액(최소 $1,117.50, 즉 액면가의 111.75%) 중 적은 금액을 받습니다. (2) 지수가 변동 없거나 5% 이하 하락 시, 투자자는 $1,000 원금을 돌려받습니다. (3) 5% 버퍼를 초과하는 손실부터 발생하며, 추가 1% 하락 시마다 원금의 1%가 감소하여 최소 지급액인 $50(액면가의 5%)까지 손실이 발생할 수 있어 최대 95% 손실에 노출됩니다.

Barclays는 초기 공정가치를 $924~$974로 추정하며, 이는 $1,000 제안가보다 낮으며 판매 수수료(노트당 총 $22.50) 및 헤지/구조화 비용을 반영한 것입니다. 이 노트는 상장되지 않으며, Barclays Capital Inc.가 시장 조성자가 될 수 있으나 의무는 아닙니다.

주요 위험으로는 (i) Barclays Bank PLC의 신용 위험, (ii) 영국의 베일인 권한으로 인해 증권의 감액 또는 전환 가능성, (iii) 상한이 있는 상승 잠재력, 높은 하락 위험 및 유동성 부족, (iv) 미국 세금 처리 불확실성이 있습니다. 이 상품은 S&P 500에 대해 다소 긍정적인 전망을 가진 투자자 중 배당금을 포기하고 제한된 원금 보호를 수용할 수 있는 투자자를 대상으로 합니다.

Barclays Bank PLC commercialise une note structurée non garantie de 14 mois – les Buffered Performance Leveraged Upside Securities (Buffered PLUS) – liées à l'indice S&P 500. Les notes ne versent aucun coupon ; le rendement est versé uniquement à l'échéance, le 16 septembre 2026.

Mécanisme de paiement : (1) Si l'indice clôture au-dessus de son niveau initial à la date d'évaluation, les détenteurs reçoivent le moindre entre (a) 1 000 $ plus 150 % de la hausse de l'indice et (b) le paiement maximum (au moins 1 117,50 $, soit 111,75 % du pair). (2) Si l'indice est stable ou en baisse jusqu'à 5 %, les investisseurs récupèrent le capital de 1 000 $. (3) Les pertes commencent au-delà de la marge tampon de 5 % ; chaque baisse supplémentaire de 1 % réduit 1 % du capital jusqu'au paiement minimum de 50 $ (5 % du pair), exposant les investisseurs à une perte maximale de 95 %.

Barclays estime la juste valeur initiale entre 924 $ et 974 $, inférieure au prix d'offre de 1 000 $, reflétant les commissions de vente (22,50 $ par note) et les coûts de couverture/structuration. Les notes ne seront pas cotées ; Barclays Capital Inc. peut assurer un marché mais n'y est pas obligé.

Risques clés : (i) risque de crédit de Barclays Bank PLC ; (ii) pouvoir de renflouement (bail-in) au Royaume-Uni pouvant entraîner une dépréciation ou une conversion des titres ; (iii) potentiel de gain plafonné, forte exposition à la baisse et illiquidité ; (iv) traitement fiscal américain incertain. Ce produit s'adresse aux investisseurs modérément optimistes sur le S&P 500, prêts à renoncer aux dividendes et à accepter une protection limitée du capital.

Barclays Bank PLC bietet eine unbesicherte strukturierte Note mit 14-monatiger Laufzeit an – die Buffered Performance Leveraged Upside Securities (Buffered PLUS) – die an den S&P 500 Index gekoppelt ist. Die Notes zahlen keine Kupons; die Rendite für den Anleger wird erst bei Fälligkeit am 16. September 2026 ausgezahlt.

Auszahlungsmechanismus: (1) Schließt der Index am Bewertungstag über seinem Anfangswert, erhalten die Inhaber den geringeren Betrag aus (a) $1.000 plus 150% des Indexzuwachses und (b) der maximalen Auszahlung (mindestens $1.117,50, also 111,75% des Nennwerts). (2) Liegt der Index unverändert oder bis zu 5% im Minus, erhalten die Anleger ihre $1.000 Kapital zurück. (3) Verluste beginnen über dem 5%igen Buffer; jeder weitere 1%-Rückgang mindert 1% des Kapitals bis zur Minimalzahlung von $50 (5% des Nennwerts), wodurch Anleger einem Verlust von bis zu 95% ausgesetzt sind.

Barclays schätzt den anfänglichen fairen Wert auf $924–$974, unter dem Angebotspreis von $1.000, was Verkaufsprovisionen (insgesamt $22,50 pro Note) sowie Absicherungs- und Strukturierungskosten widerspiegelt. Die Notes werden nicht börslich gehandelt; Barclays Capital Inc. kann als Market Maker auftreten, ist dazu aber nicht verpflichtet.

Hauptrisiken sind: (i) Kreditrisiko von Barclays Bank PLC; (ii) UK-Bail-in-Maßnahmen, die zu Abschreibungen oder Umwandlungen der Wertpapiere führen können; (iii) begrenztes Aufwärtspotenzial, hohes Abwärtsrisiko und Illiquidität; (iv) unsichere US-Steuerbehandlung. Das Produkt richtet sich an Anleger mit moderat bullischer Sicht auf den S&P 500, die auf Dividenden verzichten und eine begrenzte Kapitalsicherung akzeptieren können.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Sanjiv

(Last) (First) (Middle)
C/O RELAY THERAPEUTICS, INC.
60 HAMPSHIRE STREET

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 A(1) V 5,000 A $2.94(2) 826,667(3) D
Common Stock 199,548 I By The Patel Family Irrevocable Trust of 2019(4)
Common Stock 687,355 I By The SSP Irrevocable Trust of 2020(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
2. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.
3. Includes 410,560 shares underlying RSUs.
4. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Brian Adams, as Attorney-in-Fact 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How does the 150% leverage on Barclays Buffered PLUS work?

At maturity you receive 1.5× the S&P 500 gain, up to the maximum payment of at least $1,117.50 per $1,000 note.

What happens if the S&P 500 falls more than 5% before the September 11 2026 valuation date?

Principal is reduced dollar-for-dollar beyond the 5% buffer, with a floor payment of $50, meaning up to a 95% loss.

Is the Buffered PLUS protected by deposit insurance or a third-party guarantee?

No. The note is an unsecured, unsubordinated obligation of Barclays Bank PLC and is not FDIC-insured or otherwise guaranteed.

Can I sell the Buffered PLUS before maturity?

Possibly, but Barclays is not required to make a market and the price may be well below issue price and estimated value.

Why is the estimated value ($924–$974) lower than the $1,000 offer price?

The difference reflects sales commissions, structuring fees, hedging costs and Barclays’ funding spread.

What is the impact of the U.K. Bail-in Power on these notes?

If enacted, regulators could write down, convert or cancel the notes, causing partial or total loss irrespective of market performance.
Relay Therapeutics, Inc.

NASDAQ:RLAY

RLAY Rankings

RLAY Latest News

RLAY Latest SEC Filings

RLAY Stock Data

608.63M
139.67M
1.8%
99.33%
9.55%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE